心血管风险评估的新兴标记物  

Emerging Markers for Cardiovascular Risk Assessment

作　　者：周文丽 王营忠[1] 

机构地区：[1]延安大学附属医院冠心病二病区,陕西 延安

出　　处：《临床医学进展》2022年第10期9155-9161,共7页Advances in Clinical Medicine

摘　　要：冠状动脉疾病(Coronary Artery Disease, CAD)治疗的传统方法主要集中在低密度脂蛋白胆固醇(LDL-C)上,这通常被认为是动脉粥样硬化进展的关键危险因素。尽管它在预测CAD风险方面广泛使用,但由于一些限制,它已成为次优标志物,最近,甘油三酯、非高密度脂蛋白胆固醇(non-high-density lipoprotein cholesterol, N-HDL-C)或载脂蛋白B (apolipoprotein B, ApoB)已被证实是冠状动脉疾病风险的更可靠预测因子。故本综述概述甘油三酯、N-HDL-C、ApoB对CAD的应用价值,突出三者的可靠性和有效性,从而为将来三者可作为降脂的治疗目标提供依据,纳入常规脂质检查,以便更好地评估CAD。The traditional approach to the management of coronary artery disease (CAD) focuses mainly on low density lipoprotein cholesterol (LDL-C) which is often considered a crucial risk factor for the progression of atherosclerosis. Despite its extensive use in predicting CAD risk, it has become a sub-optimal marker owing to several limitations. Recently, Triglycerides, non-high-density lipopro-tein cholesterol (N-HDL-C) or apolipoprotein B (ApoB) have been proven to be more reliable pre-dictors of coronary artery disease risk. Therefore, this review summarizes the application value of triglyceride, N-HDL-C and ApoB in CAD, highlighting the reliability and effectiveness of the three, so as to provide a basis for them to be used as lipid-lowering therapeutic targets in the future, and to be included in routine lipid examination, so as to better evaluate CAD.

关 键 词：载脂蛋白B 冠状动脉疾病 甘油三酯 非高密度脂蛋白-C 

分 类 号：R543[医药卫生—心血管疾病]